Jeff Jensen MD/PhD
@drjensen.bsky.social
I am a lung cancer medical oncologist researching NUT carcinoma and PRAME
I thought the breakthrough of the year was PRAME in NUT carcinoma but looks like renewables won instead www.science.org/content/arti...
Science’s 2025 Breakthrough of the Year: The unstoppable rise of renewable energy
Clean energy infrastructure is being deployed with unmatched scale and speed—and China is leading the way
www.science.org
December 19, 2025 at 1:13 AM
I thought the breakthrough of the year was PRAME in NUT carcinoma but looks like renewables won instead www.science.org/content/arti...
Passed my American Board of Internal Medicine Medical Oncology boards. Woooooo
December 9, 2025 at 3:02 PM
Passed my American Board of Internal Medicine Medical Oncology boards. Woooooo
www.fda.gov/drugs/resour...
Great drug but dysgeusia a major draw back
Great drug but dysgeusia a major draw back
FDA grants traditional approval to tarlatamab-dlle for extensive stage
On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage s
www.fda.gov
December 8, 2025 at 6:40 PM
www.fda.gov/drugs/resour...
Great drug but dysgeusia a major draw back
Great drug but dysgeusia a major draw back
Another reason to love trilaciclib: less clonal hematopoiesis. Congratulations to Kelly Bolton Lab for a great study.
doi.org/10.1182/bloo...
doi.org/10.1182/bloo...
CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis
AbstractTherapy-related myeloid neoplasms (tMN) are a fatal consequence of exposure to oncologic therapy. Prior work has demonstrated that the expansion of
doi.org
December 7, 2025 at 9:09 PM
Another reason to love trilaciclib: less clonal hematopoiesis. Congratulations to Kelly Bolton Lab for a great study.
doi.org/10.1182/bloo...
doi.org/10.1182/bloo...
Reposted by Jeff Jensen MD/PhD
Congrats @RashaCosman on late breaking oral presentation, showcasing safety and MOA of novel in vivo CAR targeting TROP2 expressing tumors #SITC25 @NECTANSW - led trial from 🇦🇺 👏.
This technology will expand access to solid tumor cell therapy 🌟
This technology will expand access to solid tumor cell therapy 🌟
November 7, 2025 at 7:29 PM
Congrats @RashaCosman on late breaking oral presentation, showcasing safety and MOA of novel in vivo CAR targeting TROP2 expressing tumors #SITC25 @NECTANSW - led trial from 🇦🇺 👏.
This technology will expand access to solid tumor cell therapy 🌟
This technology will expand access to solid tumor cell therapy 🌟